A novel stratification framework for predicting outcome in patients with prostate cancer
In all the madness I forgot to post about our latest publication published last Friday: A novel stratification framework for predicting outcome in patients with prostate cancer. Found in the British Journal of Cancer.
We have discovered why some prostate cancers are more aggressive, spread to different parts of the body, and ultimately cause death.
Recently we developed a test to distinguish aggressive prostate cancers from less threatening forms of the disease, by applying some complex maths known as Latent Process Decomposition, that will help avoid sometimes-damaging unnecessary treatment. This aggressive form of prostate cancer is known as DESNT - which has the worst clinical outcomes for patients. In this study we carry on this work and studied gene expression levels in 1,785 prostate cancer tumour samples.
We show how the number of ‘aggressive’ cells in a tumour sample defines how quickly the disease will progress and spread. The more DESNT cells, the quicker the patient is likely to progress. We also revealed three new subtypes of prostate cancer that could be used to stratify patients for different treatments.
The research was funded by the Bob Champion Cancer Trust, the Masonic Charitable Foundation, the King Family, the Hargrave Foundation, and UEA, with support from Movember, Prostate Cancer UK, Callum Barton and from the Andy Ripley Memorial Fund.
https://doi.org/10.1038/s41416-020-0799-5
Kudos link: https://www.growkudos.com/publications/10.1038%25252Fs41416-020-0799-5/reader
We have discovered why some prostate cancers are more aggressive, spread to different parts of the body, and ultimately cause death.
Recently we developed a test to distinguish aggressive prostate cancers from less threatening forms of the disease, by applying some complex maths known as Latent Process Decomposition, that will help avoid sometimes-damaging unnecessary treatment. This aggressive form of prostate cancer is known as DESNT - which has the worst clinical outcomes for patients. In this study we carry on this work and studied gene expression levels in 1,785 prostate cancer tumour samples.
We show how the number of ‘aggressive’ cells in a tumour sample defines how quickly the disease will progress and spread. The more DESNT cells, the quicker the patient is likely to progress. We also revealed three new subtypes of prostate cancer that could be used to stratify patients for different treatments.
The research was funded by the Bob Champion Cancer Trust, the Masonic Charitable Foundation, the King Family, the Hargrave Foundation, and UEA, with support from Movember, Prostate Cancer UK, Callum Barton and from the Andy Ripley Memorial Fund.
https://doi.org/10.1038/s41416-020-0799-5
Kudos link: https://www.growkudos.com/publications/10.1038%25252Fs41416-020-0799-5/reader
Comments